Biotechnology News and Research

RSS

Advanced Instruments launches three new levels of Osmometer Standard Solutions

Advanced Instruments is pleased to introduce three new levels of Osmometer Standard Solutions to its product offering. The 200, 400 and 1000 mOsm/kg H20 level standards are NIST- traceable salt solutions that are packaged in 2mL ampules, 10 ampules per box. The kits are available for immediate release.

31 Mar 2010

PhRMA report: 234 medicines in development for special health care needs of children

America's pharmaceutical research and biotechnology companies are developing 234 medicines for the special health care needs of children, according to a new report released today by the Pharmaceutical Research and Manufacturers of America.

31 Mar 2010

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.

31 Mar 2010

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

“As explained in the ruling yesterday, the District Court's determination is only a preliminary step in the legal process that does not affect how the U.S. Patent and Trademark Office (PTO) evaluates patent applications relating to DNA-based inventions.”

31 Mar 2010

MDS to accept for purchase and cancellation 52.9M common shares at $8.50 per share

MDS Inc., a leading provider of products and services to the global health science markets, today announced results of its substantial issuer bid, which expired at 5 p.m. (Eastern time) on March 29, 2010.

31 Mar 2010

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

The Fairbanks Institute for Healthy Communities, the Indianapolis not-for-profit organization working to improve community health, and BioServe, a global provider of biomaterial and genetic research services, today announced that they will co-market INbank™, a next generation biorepository that was recently launched by The Fairbanks Institute.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

Despite stagnant economy, total employment in Ohio's bioscience sector increased by 2.8%

Employment in Ohio's biosciences sector is on the rise across the state according to a report released today by BioOhio, a non-profit organization supported by the Thomas Edison Program of the Ohio Department of Development.

31 Mar 2010

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.

31 Mar 2010

FDA accepts filing of Lux Biosciences' NDA for Luveniq and grants application priority review

Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration has accepted the filing of the company's New Drug Application for Luveniq™ (oral voclosporin) and has granted the application priority review.

31 Mar 2010

CryoLife files emergency motion for preliminary injunction against Medafor

CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it filed an emergency motion for a preliminary injunction against Medafor, Inc. in the United States District Court for the Northern District of Georgia, Atlanta division. CryoLife contends that Medafor is improperly attempting to terminate the exclusive distribution agreement ("EDA") between the parties, and CryoLife has requested that the Court enjoin Medafor from proceeding with the termination.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Close-ups on how the health overhaul gives and takes away

"An association representing 300 large corporations urged President Obama and Congress on Monday to repeal a provision of the health care overhaul that prompted AT&T, Caterpillar and other companies to announce substantial charges for the current quarter."

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

Hospira acquires Orchid's injectables formulations business

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million.

31 Mar 2010

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV. The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application for KRYSTEXXA™ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy.

30 Mar 2010

USPTO issues patent for Incisive Surgical's proprietary INSORB Absorbable Skin Stapling Technology

Incisive Surgical, Inc. today announced that the U.S. Patent and Trademark office has issued the company a patent for its proprietary INSORB® Absorbable Skin Stapling Technology. The patent broadly covers the wound closure stapling apparatus.

30 Mar 2010

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.

30 Mar 2010

Biotechnology News and Research

Advanced Instruments launches three new levels of Osmometer Standard Solutions

PhRMA report: 234 medicines in development for special health care needs of children

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

MDS to accept for purchase and cancellation 52.9M common shares at $8.50 per share

Fairbanks Institute and BioServe to co-market next generation biorepository, INbank

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

Despite stagnant economy, total employment in Ohio's bioscience sector increased by 2.8%

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

FDA accepts filing of Lux Biosciences' NDA for Luveniq and grants application priority review

CryoLife files emergency motion for preliminary injunction against Medafor

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Close-ups on how the health overhaul gives and takes away

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Hospira acquires Orchid's injectables formulations business

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Savient Pharmaceuticals' resubmission of BLA for KRYSTEXXA accepted for FDA review

USPTO issues patent for Incisive Surgical's proprietary INSORB Absorbable Skin Stapling Technology

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News